ESR1 and breast carcinoma: In addition, it should be noted that the results presented in the present study are limited to a representative triple negative (MDA-MB-231) and to a representative ER+ (MCF-7) breast cancer cell line; using other breast cancer cells expressing varying levels of ERRα would strengthen the clinical implications of the current study.